FDA Must Present "Convincing Rationale" For Bioequivalence Changes
Executive Summary
FDA has not presented a "convincing rationale" for its proposed changes to bioequivalence requirements, the Pharmaceutical Research & Manufacturers of America said in March 2 comments on FDA's draft guidance for "In Vivo Bioequivalence Studies Based on Population and Individual Approaches."